Piston Bio — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Piston Bio is an early-stage biotech leveraging proprietary protein engineering technology to design next-generation biologic drugs, starting with cytokines. The company appears to be in a pre-clinical or discovery stage, building its platform and initial pipeline. As a private, pre-revenue entity, its near-term goals likely involve platform validation, pipeline advancement, and securing additional partnership or investment capital to fund development.

OncologyImmunology

Technology Platform

Proprietary protein engineering platform focused on designing novel cytokine therapeutics with improved pharmacological properties.

Opportunities

The engineered cytokine market represents a multi-billion dollar opportunity to overcome historical toxicity hurdles of native cytokines.

A validated platform also offers horizontal expansion into other difficult-to-drug protein classes, creating significant partnership and pipeline potential.

Risk Factors

High technical risk that the platform fails to produce clinically differentiated candidates.

Financial risk as a pre-revenue company dependent on venture funding.

Intense competition from other biotechs and large pharma in the cytokine engineering space.

Competitive Landscape

The cytokine engineering field is competitive, with several companies like Synthekine, Senti Bio, and Alkermes' Cytokine Fusion program, alongside large pharma efforts. Piston Bio must demonstrate a unique engineering approach and superior product profiles to secure a position.

More companies in Biologics / Biosimilars →More companies in United States →